PMID- 23138352
OWN - NLM
STAT- MEDLINE
DCOM- 20130814
LR  - 20211021
IS  - 1435-5604 (Electronic)
IS  - 0914-8779 (Linking)
VI  - 31
IP  - 2
DP  - 2013 Mar
TI  - The effects of risedronate administered in combination with a proton pump 
      inhibitor for the treatment of osteoporosis.
PG  - 206-11
LID - 10.1007/s00774-012-0406-9 [doi]
AB  - This study was performed to investigate the effects of the co-administration of 
      proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for 
      osteoporosis. A total of 180 women with low bone mineral density were randomly 
      divided into four groups, one in which sodium risedronate was administered with 
      sodium rabeprazole and one in which only risedronate was administered (BP + PPI 
      and BP groups, respectively). The biomarkers were measured at the baseline and 
      every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected 
      for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, 
      bone mineral density (BMD) of the lumbar spine and physical parameters evaluated 
      according to the SF-36v2 Health Survey. Statistical comparisons of these 
      parameters were performed after 9 months. Data were available for a total of 137 
      patients (62 in the BP group and 75 in the BP + PPI group). The Delta % value of 
      increase in BMD and improvement of physical functioning in the BP + PPI group 
      were significantly larger, and its decrease in BAP in the BP + PPI group was 
      significantly smaller than that in the BP group. It is expected that risedronate 
      administration in combination with a PPI may be more effective not only for 
      treating osteoporosis but also improving physical fitness than treatment with 
      risedronate alone.
FAU - Itoh, Soichiro
AU  - Itoh S
AD  - Department of Orthopaedic Surgery, Kawakita General Hospital, 1-7-3 Asagaya-kita, 
      Suginami-ku, Tokyo 166-8588, Japan. itoso.gene@gmail.com
FAU - Sekino, Yohichi
AU  - Sekino Y
FAU - Shinomiya, Ken-ichi
AU  - Shinomiya K
FAU - Takeda, Shu
AU  - Takeda S
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20121110
PL  - Japan
TA  - J Bone Miner Metab
JT  - Journal of bone and mineral metabolism
JID - 9436705
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - KM2Z91756Z (Risedronic Acid)
RN  - M2F465ROXU (Etidronic Acid)
SB  - IM
MH  - Bone Density Conservation Agents/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Etidronic Acid/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Osteoporosis/complications/*drug therapy
MH  - Osteoporotic Fractures/complications/drug therapy
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects/*therapeutic use
MH  - Risedronic Acid
EDAT- 2012/11/10 06:00
MHDA- 2013/08/15 06:00
CRDT- 2012/11/10 06:00
PHST- 2012/04/10 00:00 [received]
PHST- 2012/10/21 00:00 [accepted]
PHST- 2012/11/10 06:00 [entrez]
PHST- 2012/11/10 06:00 [pubmed]
PHST- 2013/08/15 06:00 [medline]
AID - 10.1007/s00774-012-0406-9 [doi]
PST - ppublish
SO  - J Bone Miner Metab. 2013 Mar;31(2):206-11. doi: 10.1007/s00774-012-0406-9. Epub 
      2012 Nov 10.